Qualigen Granted New Patents Covering 25 Countries
Qualigen Therapeutics (NASDAQ: QLGN) has announced significant patent developments for its drug QN-302 in the first half of 2025. The company has secured patents titled "Substitued Naphthalene Diimides and Their Use" across 25 countries, including major markets in Europe, India, China, and Russia.
The drug, originally developed by Professor Stephen Neidle's team at University College London and licensed by Qualigen, is targeted at treating Pancreatic and Gastrointestinal Cancer. These patents, which extend into 2040, cover both the product and its manufacturing methods.
Qualigen Therapeutics (NASDAQ: QLGN) ha annunciato importanti sviluppi brevettuali per il suo farmaco QN-302 nella prima metà del 2025. L'azienda ha ottenuto brevetti intitolati "Nafthalene Diimidi Sostituiti e il loro utilizzo" in 25 paesi, inclusi i principali mercati di Europa, India, Cina e Russia.
Il farmaco, originariamente sviluppato dal team del Professor Stephen Neidle presso l'University College London e concesso in licenza a Qualigen, è destinato al trattamento del cancro pancreatico e gastrointestinale. Questi brevetti, validi fino al 2040, coprono sia il prodotto che i metodi di produzione.
Qualigen Therapeutics (NASDAQ: QLGN) ha anunciado importantes avances en patentes para su medicamento QN-302 durante la primera mitad de 2025. La compañía ha asegurado patentes tituladas "Diimidas de Naftaleno Sustituidas y su Uso" en 25 países, incluyendo mercados clave en Europa, India, China y Rusia.
El medicamento, desarrollado originalmente por el equipo del Profesor Stephen Neidle en University College London y licenciado a Qualigen, está dirigido al tratamiento del cáncer pancreático y gastrointestinal. Estas patentes, que se extienden hasta el 2040, cubren tanto el producto como sus métodos de fabricación.
Qualigen Therapeutics (NASDAQ: QLGN)는 2025년 상반기에 자사 약물 QN-302에 대한 중요한 특허 개발을 발표했습니다. 이 회사는 "치환 나프탈렌 디이미드 및 그 용도"라는 제목의 특허를 25개국에서 확보했으며, 여기에는 유럽, 인도, 중국, 러시아의 주요 시장이 포함됩니다.
이 약물은 원래 University College London의 Stephen Neidle 교수 팀이 개발하고 Qualigen이 라이선스를 받은 것으로, 췌장암 및 위장관암 치료를 목표로 합니다. 이 특허들은 2040년까지 유효하며 제품과 제조 방법 모두를 포함합니다.
Qualigen Therapeutics (NASDAQ : QLGN) a annoncé des avancées significatives en matière de brevets pour son médicament QN-302 au cours du premier semestre 2025. La société a obtenu des brevets intitulés « Diimides de Naphtalène Substitués et Leur Utilisation » dans 25 pays, incluant des marchés majeurs en Europe, en Inde, en Chine et en Russie.
Le médicament, initialement développé par l'équipe du professeur Stephen Neidle à l'University College London et licencié par Qualigen, vise à traiter le cancer du pancréas et gastro-intestinal. Ces brevets, valables jusqu'en 2040, couvrent à la fois le produit et ses procédés de fabrication.
Qualigen Therapeutics (NASDAQ: QLGN) hat bedeutende Patentanmeldungen für sein Medikament QN-302 in der ersten Hälfte des Jahres 2025 bekannt gegeben. Das Unternehmen hat Patente mit dem Titel „Substituierte Naphthalin-Diimide und deren Verwendung“ in 25 Ländern gesichert, darunter wichtige Märkte in Europa, Indien, China und Russland.
Das Medikament, ursprünglich vom Team des Professors Stephen Neidle am University College London entwickelt und von Qualigen lizenziert, zielt auf die Behandlung von Bauchspeicheldrüsen- und Magen-Darm-Krebs ab. Diese Patente, die bis 2040 gültig sind, umfassen sowohl das Produkt als auch die Herstellungsverfahren.
- Patent protection secured in 25 countries including major markets like China, India, and Russia
- Long-term patent protection extending to 2040
- Patents cover both product and manufacturing methods
- Strong IP position for potential pancreatic and gastrointestinal cancer treatment
- None.
CARLSBAD, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company” or “Qualigen”) is announcing an update on patents granted in the first six months of 2025. The patent is Titled “Substitued Naphthalene Diimides and Their Use.” The patent is for the drug, which was developed by Professor Stephen Neidle and his team at the University College of London, and is licensed by Qualigen Therapeutics, QN-302. These patents cover the product and their methods of manufacturing.
Through validations and process across Europe these patents were granted and cover the majority of the Euoprean population. In total over 20 countries in Europe have patent coverage for QN-302. Qualigen has also been granted similar patent coverage in India, China and Russia. The expiration on these patents extends into 2040. “Having the patents granted covering so much of the world’s population strengthens our position as a drug development company. By assuring such strong coverage will allow us to continue bringing QN-302 to market and treating patients suffering from Pancreatic and Gastrointestinal Cancer.”, stated Kevin Richardson II, CEO of Qualigen. Qualigen will provide periodic updates on new patents granted, as there are a number which have been published and others which are pending.
About Qualigen Therapeutics, Inc.
For more information about Qualigen Therapeutics, Inc., please visit www.qlgntx.com. Information on the Company’s website does not constitute a part of and is not incorporated by reference into this press release.
Forward-Looking Statements
This news release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company may in some cases use terms such as “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “likely,” “will,” “should” or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. The Company’s forward-looking statements are based on current beliefs and expectations of its management team that involve risks, potential changes in circumstances, assumptions, and uncertainties, including statements regarding the timing of the offering. Any or all of the forward-looking statements may turn out to be wrong or be affected by assumptions the Company makes that later turn out to be incorrect, or by known or unknown risks and uncertainties. These forward-looking statements are subject to risks and uncertainties including risks related to the Company’s ability to regain compliance with Nasdaq’s continued listing requirements, including the Company’s ability to file its Form 10-Q for the period ended September 30, 2024, or otherwise in the future, or otherwise maintain compliance with any other listing requirement of The Nasdaq Capital Market, the potential de-listing of the Company’s shares from The Nasdaq Capital Market due to its failure to comply with the Nasdaq’s continued listing requirement, or its alternatives, or otherwise in the future, and the other risks set forth in the Company’s filings with the Securities and Exchange Commission, including in its Annual Reports on Form 10-K and its Quarterly Reports on Form 10-Q. For all these reasons, actual results and developments could be materially different from those expressed in or implied by the Company’s forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this news release. The Company disclaims any intent or obligation to update these forward-looking statements beyond the date of this news release, except as required by law. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Contact:
Investor Relations
ir@qlgntx.com.
FAQ
What new patents did Qualigen (QLGN) receive in 2025?
What is Qualigen's QN-302 drug designed to treat?
How long will Qualigen's new patents last?
Who developed the technology behind Qualigen's QN-302?
Which major markets are covered by Qualigen's new patents?
